使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Greetings. Welcome to the Apyx Medical fourth quarter and full year 2024 conference call. (Operator Instructions) As a reminder, this conference is being recorded.
各位好。歡迎參加 Apyx Medical 2024 年第四季暨全年電話法說會。(接線員指示) 提醒各位,本次會議將被錄音。
It's now my pleasure to introduce Jeremy Feffer with Investor Relations. Jeremy, you may begin.
現在很榮幸為各位介紹投資人關係部的 Jeremy Feffer。Jeremy,請開始。
Jeremy Feffer - Investor Relations
Jeremy Feffer - Investor Relations
Thank you and welcome everyone to our fourth quarter and full year 2024 earnings call. Representing the company on the call are Charlie Goodwin, Chief Executive Officer; and Matt Hill, Chief Financial Officer of Apyx.
謝謝,並歡迎各位參加我們 2024 年第四季暨全年財報電話會議。代表公司出席本次電話會議的有:Apyx 執行長 Charlie Goodwin,以及財務長 Matt Hill。
Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including without limitation, those identified in the risk factors section of our most recent annual report on Form 10-K, our most recent 10-Q filing, and the company's other filings with the Securities and Exchange Commission.
在開始之前,我想提醒各位,我們今天的發言以及對各位提問的回應可能包含前瞻性陳述,這些陳述係基於管理階層目前的預期,並涉及固有風險與不確定性,可能導致實際結果與所示內容出現重大差異,包括但不限於我們最近一期 Form 10-K 年報、最近一期 10-Q 申報,以及公司向美國證券交易委員會(SEC)提交之其他文件中的風險因素章節所揭露者。
Such factors may be updated from time to time in our filings with the SEC, which are available on our website. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events, or otherwise.
相關因素可能會不時在我們向 SEC 提交的文件中更新,這些文件可於我們網站查閱。因新資訊、未來事件或其他原因,我們不承擔公開更新或修訂前瞻性陳述之義務。
This call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We generally refer to these as non-GAAP financial measures.
本次電話會議也將提及若干未依一般公認會計原則(GAAP)計算的財務衡量指標。我們通常將其稱為非 GAAP 財務衡量指標。
Reconciliations of those non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the investor relations portion of our website.
上述非 GAAP 財務衡量指標與依 GAAP 計算並呈列之最可比衡量指標的調節表,已刊載於我們網站投資人關係專區的財報新聞稿中。
I would now like to turn the call over to Mr. Charlie Goodwin, Apyx Medical's President and Chief Executive Officer. Charlie, please go ahead.
現在我想把電話會議交給 Apyx Medical 總裁兼執行長 Charlie Goodwin 先生。Charlie,請。
Charles Goodwin - President and Chief Executive Officer
Charles Goodwin - President and Chief Executive Officer
Thank you, Jeremy, and thank you all for joining us today. Per our usual format on these quarterly calls, I will be providing a review of our performance in the fourth quarter and full year 2024, and then I will turn the call over to Matt for a review of our fourth quarter and full year 2024 financial results, as well as our full year 2025 guidance. We will then open the call for questions.
謝謝你,Jeremy,也謝謝各位今天加入我們。依照我們季度電話會議的一貫流程,我將先回顧 2024 年第四季與全年營運表現,接著把電話交給 Matt,請他說明 2024 年第四季與全年財務結果,以及 2025 年全年財測指引。之後我們將開放提問。
Let me start with a review of our fourth quarter performance. We reported total revenue of $14.2 million for the quarter, a slight decrease of 3% compared to $14.7 million for the same period last year.
我先從第四季表現回顧開始。我們本季總營收為 1,420 萬美元,較去年同期的 1,470 萬美元小幅下降 3%。
Looking at this by segment, sales of our advanced energy products exceeded our expectations for the fourth quarter at $12.1 million, which is essentially flat year over year. To this point, we were pleased to report that the advanced energy segment grew 30% compared with the sequential third quarter of 2024.
按事業部來看,我們的先進能量產品第四季銷售額為 1,210 萬美元,優於我們的預期,年對年基本持平。此外,我們也很高興報告,先進能量事業部相較 2024 年第三季呈現 30% 的季增。
This reflects the stronger sales of single-use handpieces and the approved capital equipment sales in the second half where we more than doubled the unit shipped. While it's too early to say that two quarters of data make a trend, we are encouraged by this momentum and are hopeful that we can build on it as we move into 2025.
這反映了一次性手持器銷售更強勁,以及下半年已核准的資本設備銷售,我們的出貨台數較前期增加逾一倍。雖然現在就說兩季數據形成趨勢仍為時過早,但我們對這股動能感到鼓舞,並希望在邁入 2025 年時能持續累積。
The softness in the aesthetic space throughout the last 18 months is not specific to our business, as companies face similar challenges due to the macroeconomic environment and the rapid adoption of GLP-1 drugs for weight loss.
過去 18 個月醫美市場的疲弱並非我們獨有;在總體經濟環境影響以及 GLP-1 減重藥物快速普及之下,許多公司都面臨類似挑戰。
We believe the use of GLP-1s has caused patients to delay aesthetic treatments as their discretionary funds have been diverted to paying for GLP-1 drugs. These drugs can range in price from about $300 for compounded versions and up to $1,800 a month for branded cash pay options.
我們認為,GLP-1 的使用使患者延後接受醫美療程,因為其可支配資金被轉用於支付 GLP-1 藥物費用。這些藥物的價格約從複方版本每月 300 美元起,到品牌自費選項每月最高可達 1,800 美元。
In addition to the financial commitment, we believe patients are postponing aesthetic procedures until they reach their ideal weight. Importantly, we do not believe non-invasive procedures which you normally see offered at the MedSpas will be effective treatments for the loose and lax skin that many patients see after the weight loss associated with the use of the GLP-1s.
除了財務承諾之外,我們也認為患者會等到達到理想體重後才進行醫美手術。重要的是,我們不認為一般在醫美診所(MedSpa)提供的非侵入式療程,能有效改善許多患者在使用 GLP-1 減重後出現的皮膚鬆弛與下垂問題。
We believe all the factors I just mentioned have contributed to declining revenues for plastic and cosmetic surgeons beginning in 2023 and continuing through '24, causing many physicians to delay the purchase of capital equipment.
我們認為,我剛才提到的所有因素,已導致整形外科與醫美外科醫師自 2023 年起至 2024 年營收下滑,使許多醫師延後購置資本設備。
However, we believe the wave of GLP-1 patients that have reached their weight loss goal over the past 12 to 18 months will be seeking a surgical solution. As the only true surgical aesthetics company, we believe our Renuvion system is uniquely positioned to help surgeons capitalize on this burgeoning tailwind.
然而,我們認為在過去 12 至 18 個月中,已有一波 GLP-1 患者達成減重目標,接下來將尋求手術解決方案。作為唯一真正的外科醫美公司,我們相信 Renuvion 系統具備獨特定位,可協助外科醫師把握這股快速成長的利多動能。
Unlike others in the industry, we have proprietary technology that can address these patients' needs, offering Renuvion as the only FDA cleared device for use following liposuction in body contouring procedures.
不同於產業內其他公司,我們擁有可滿足這些患者需求的專有技術;Renuvion 是唯一獲 FDA 核准可於抽脂後用於體雕手術的設備。
We believe this minimally invasive surgical procedure is the best treatment option to address loose and lax skin, providing a durable and transformational result. This is because of the significant amount of loose and lax skin that these patients will typically have after losing 15% to 20% of their total body weight. It is our belief Renuvion should be the standard of care for these patients.
我們相信,這項微創手術是改善皮膚鬆弛與下垂的最佳治療選擇,能帶來持久且具轉變性的效果。原因在於,這些患者在減去其總體重的 15% 至 20% 後,通常會出現大量皮膚鬆弛與下垂。我們認為,Renuvion 應成為這類患者的標準照護(standard of care)。
To amplify our message, we have been executing our direct to consumer marketing strategy with outstanding results. Since launching in Q2 of 2024, this program has delivered significant reach, views, and PR beyond our expectations.
為了放大我們的訊息,我們一直在執行直接面向消費者(DTC)的行銷策略,並取得非常出色的成果。自 2024 年第二季啟動以來,該計畫在觸及、觀看與公關聲量方面都顯著超出我們預期。
We surpassed our media placement goal by 187% and exceeded our impressions goal by over 13,000%. Our brand has been featured in People, Oprah Daily, Glamour, Well and Good, and more. We have also leveraged the influence of [Funmi Monet and Dolores Cantania], each bringing a unique voice and engaged audience to our campaign.
我們的媒體露出目標超標 187%,曝光(impressions)目標更是超出逾 13,000%。我們的品牌已登上 People、Oprah Daily、Glamour、Well and Good 等媒體及更多平台。我們也運用 [Funmi Monet and Dolores Cantania] 的影響力,兩位各自以獨特觀點與高度互動的受眾為本次活動助力。
Their messaging around body confidence, looking and feeling your best, and the importance of skin tightening post GLP-1 weight loss has resonated strongly with consumers. Through their authentic storytelling and our strategic campaign execution, we have driven strong engagement, increased brand awareness, and elevated our consumer demand. We are the number one trusted body contouring technology by doctors.
她們圍繞身體自信、展現與感受最佳狀態,以及 GLP-1 減重後皮膚緊緻重要性的訊息,已強烈引起消費者共鳴。透過她們真誠的故事分享與我們策略性的活動執行,我們帶動了強勁互動、提升品牌知名度,並推升消費者需求。我們是醫師最信賴的第一名體雕技術。
Continuing to capitalize on the minimally invasive surgical trends, I am also excited that we recently submitted our 510(K) for the AYON Body Contouring System to the FDA, which was ahead of our original schedule by nearly 90 days.
為持續把握微創手術趨勢,我也很興奮地分享:我們近期已向 FDA 提交 AYON 體雕系統的 510(K) 申請,較原定時程提前近 90 天。
This all in one surgical platform seamlessly integrates Renuvion, ultrasound assisted liposuction, power assisted liposuction, infiltration, aspiration, electrocoagulation, and fat transfer into a single streamlined device.
這個一體式手術平台可無縫整合 Renuvion、超音波輔助抽脂(UAL)、動力輔助抽脂(PAL)、注入(infiltration)、抽吸(aspiration)、電凝(electrocoagulation)以及脂肪移植(fat transfer),全部集中於單一精簡設備中。
When we started the development of AYON, we had not anticipated the GLP weight loss revolution. However, considering the major shifts in the market. We believe AYON is a game changer for surgeons and will further differentiate us, positioning Apyx as their preferred surgical partner.
當我們開始開發 AYON 時,尚未預見 GLP 減重革命。然而,考量市場的重大變化。我們相信 AYON 將為外科醫師帶來顛覆性改變,並進一步凸顯我們的差異化,使 Apyx 成為他們首選的外科合作夥伴。
Our goal for the next few years is to be able to walk into almost any surgeon's practice and see an AYON positioned in the heart of their operating room.
我們未來幾年的目標,是幾乎走進任何外科醫師的診所,都能看到一台 AYON 擺在手術室的核心位置。
Regarding timing, we are preparing for a planned launch of AYON in the back half of 2025 pending FDA clearance. We expect this launch to kickstart our equipment sales growth as we have an opportunity to capture new market share and expand our total addressable market in aesthetic surgery.
就時程而言,在取得 FDA 核准的前提下,我們正為 2025 年下半年規劃推出 AYON 做準備。我們預期此次上市將帶動設備銷售成長,因為我們有機會取得新的市占,並擴大我們在醫美外科領域的整體可服務市場(TAM)。
For those of you interested in learning more about the AYON system and want to get an early look at this revolutionary all in one system, we invite you to visit us from March 20 through the 23 at the aesthetic meet at the Austin Convention Center in Austin, Texas. This is the premier event in aesthetics, and we are really excited to introduce AYON.
對於有興趣進一步了解 AYON 系統,並希望搶先一睹這套革命性一體化系統的各位,我們誠摯邀請您於 3 月 20 日至 23 日期間,蒞臨位於德州奧斯汀市奧斯汀會議中心(Austin Convention Center)舉辦的美學年會(Aesthetic Meet)。這是美學領域的頂級盛會,我們非常期待在此介紹 AYON。
I hope today's call along with previous announcements has helped convey just how excited we are to introduce AYON to aesthetic surgeons. We look forward to gaining traction in 2025 and providing further updates as the year progresses.
我希望今天的電話會議以及先前的公告,已協助傳達我們向美學外科醫師推出 AYON 的興奮之情。我們期待在 2025 年取得進展動能,並在年度推進過程中提供更多更新。
Before turning the call over to Matt to do a deep dive on our financial results, I wanted to remind everyone that in November of 2024, we announced a restructuring program that reduced our US workforce by nearly 25% in order to better focus, optimize, and streamline our operations. This program right sized our operations and reduced our costs given the changes in the market around the rapid adoptions of GLP-1 drugs.
在把電話會議交給 Matt 針對我們的財務結果進行深入說明之前,我想提醒各位:我們已於 2024 年 11 月宣布一項重整計畫,將美國員工人數削減近 25%,以便更聚焦、最佳化並精簡我們的營運。鑑於市場因 GLP-1 藥物快速採用而出現變化,該計畫使我們的營運規模更為適當,並降低了成本。
Our annualized future cost savings from this reduction in force is estimated to be approximately $4.3 million. Through this initiative, we also identified over $4 million of additional cost savings and anticipate our operating expenses to be below $40 million in 2025.
此次裁員所帶來的未來年度化成本節省,估計約為 430 萬美元。透過這項措施,我們也辨識出超過 400 萬美元的額外成本節省,並預期 2025 年的營業費用將低於 4,000 萬美元。
As part of a broader strategic initiative, we also announced in the fourth quarter of 2024 that we strengthened our balance sheet by completing a registered direct offering with net proceeds of approximately $6.8 million and amended our credit agreement with perceptive credit holdings.
作為更廣泛策略性計畫的一部分,我們亦於 2024 年第四季宣布,透過完成一項註冊直接發行(registered direct offering),取得約 680 萬美元的淨募資款,並修訂了我們與 Perceptive Credit Holdings 的信貸協議,以強化資產負債表。
We believe the collective actions taken in the fourth quarter have better positioned Apyx Medical for long term success.
我們相信,第四季所採取的一系列行動,已使 Apyx Medical 更有利於實現長期成功。
I will now turn the call over to Matt for a review of our fourth quarter and full year 2024 financial results in more detail along with our financial guidance for 2025, which we refined in today's release.
接下來我將把電話會議交給 Matt,更詳細檢視我們 2024 年第四季與全年財務結果,並說明我們在今日新聞稿中進一步精煉的 2025 年財務指引。
Matthew Hill - Chief Financial Officer
Matthew Hill - Chief Financial Officer
Thanks, Charlie. Before I get started, please note that all references to fourth quarter and full year financial results will be on a GAAP and year over year basis unless noted otherwise. As Charlie mentioned, total revenue for the fourth quarter '24 decreased 3% to $14.2 million compared to $14.7 million in the prior year period.
謝謝你,Charlie。在我開始之前,請注意:除非另有說明,所有對第四季與全年財務結果的提及,皆以 GAAP 及年對年(YoY)基礎呈現。如 Charlie 所提,2024 年第四季總營收較去年同期下降 3%,至 1,420 萬美元,去年同期為 1,470 萬美元。
Revenue for the advanced energy segment was flat at approximately $12.1 million as a result of increased sales of new generators and single use and pieces in the US and customer upgrades to the Apyx One Console internationally. These increases were offset by a lower average selling price of generators to domestic customers, fewer domestic customer upgrades to the Apyx One Console, and a decrease in international sales of new generators.
先進能量(advanced energy)部門營收約為 1,210 萬美元,持平,主要由於美國新型發電機以及一次性使用產品與零件的銷售增加,並且國際客戶升級至 Apyx One Console。上述增幅被以下因素抵銷:對國內客戶的發電機平均售價較低、國內客戶升級至 Apyx One Console 的數量較少,以及國際新型發電機銷售下滑。
OEM segment sales decreased 16% or approximately $0.3 million for the fourth quarter of '24 when compared to the fourth quarter of '23. The decrease in OEM sales was due to a decrease in sales volumes to existing customers.
OEM 部門銷售在 2024 年第四季較 2023 年第四季下降 16%,約 30 萬美元。OEM 銷售下滑係因對既有客戶的銷售量減少。
Domestic revenue increased 1% year over year to $10.6 million and international revenue decreased 8% year over year to $3.7 million. Gross profit for the fourth quarter '24 increased to $9 million compared with $8.9 million in the prior year period.
國內營收年增 1% 至 1,060 萬美元,國際營收年減 8% 至 370 萬美元。2024 年第四季毛利增至 900 萬美元,去年同期為 890 萬美元。
Gross profit margin for the fourth quarter '24 was 63.0% compared to 60.9% in the prior year period. The increase in gross profit margins was primarily attributable. To changes in both product mix and geographic mix within the advanced energy segment with domestic sales comprising a higher percentage of total sales. This increase was partially offset by a decrease in the average selling price of generators to domestic customers and customer mix within the OEM segment.
2024 年第四季毛利率為 63.0%,去年同期為 60.9%。毛利率提升主要歸因於先進能量部門的產品組合與地理組合變化,其中國內銷售占總銷售的比重提高。此提升部分被以下因素抵銷:對國內客戶的發電機平均售價下降,以及 OEM 部門的客戶組合變化。
Operating expenses decreased to $12 million for the fourth quarter '24 compared to $14.7 million in the prior year period. The decrease in operating expenses was driven by a $1.9 million decrease in selling, general and administrative expenses, a $0.3 million decrease in research and development expenses. A $0.3 million decrease in professional service expenses and a $0.2 million decrease in salaries and related costs.
2024 年第四季營業費用降至 1,200 萬美元,去年同期為 1,470 萬美元。營業費用下降主要由以下因素帶動:銷售、一般及行政費用減少 190 萬美元,研發費用減少 30 萬美元,專業服務費用減少 30 萬美元,以及薪資及相關成本減少 20 萬美元。
Loss from operations decreased $2.7 million or 47% to $3 million. Other expense, net for the fourth quarter '24 and '23 was $1.5 million and $3.8 million, respectively. The decrease was primarily due to the $3.1 million loss on extinguishment of the mid-cap credit agreement in the fourth quarter of '23.
營業損失減少 270 萬美元(降幅 47%)至 300 萬美元。2024 年與 2023 年第四季的其他費用(淨額)分別為 150 萬美元與 380 萬美元。下降主要係因 2023 年第四季終止中型資本(mid-cap)信貸協議所產生的 310 萬美元損失。
Net loss attributable to stockholders was $4.6 million or $0.12 per share for the fourth quarter '24 compared with $9.6 million or $0.28 per share in the prior year period.
2024 年第四季歸屬於股東的淨損為 460 萬美元(每股 0.12 美元),去年同期為 960 萬美元(每股 0.28 美元)。
Adjusted EBITDA loss decreased 53% to $2.2 million compared to $4.7 million in the fourth quarter of '23. As a reminder, we provide a detailed reconciliation from net loss and triple to stockholders to non-GAAP adjusted EBITDA loss in our earnings press release.
調整後 EBITDA 虧損較 2023 年第四季的 470 萬美元下降 53%,至 220 萬美元。提醒各位,我們在財報新聞稿中提供了從歸屬於股東的淨損到非 GAAP 調整後 EBITDA 虧損的詳細調節表。
For the three months ended December 31, 2024, cash used in operating activities increased to $2.9 million compared to $2.2 million used in the prior year period.
截至 2024 年 12 月 31 日止三個月,用於營運活動的現金增加至 290 萬美元,去年同期為 220 萬美元。
As of December 31, 2024, the company had cash and cash equivalent of $31.7 million compared to $43.7 million as of December 31, 2023.
截至 2024 年 12 月 31 日,公司持有的現金及約當現金為 3,170 萬美元;截至 2023 年 12 月 31 日為 4,370 萬美元。
In addition, during the fourth quarter of '24, we amended our credit agreement with our lender and partner, perceptive advisors, reducing our revenue covenants and adding a maximum operating expense covenants at $40 million and $45 million for '25 and '26 respectively. Associated with the amendment, we issued perceptive 150,000 shares of our common stock.
此外,在 2024 年第四季,我們與放款人暨合作夥伴 Perceptive Advisors 修訂了信貸協議,下調了營收契約條款(revenue covenants),並新增最高營業費用契約條款(maximum operating expense covenants),2025 年與 2026 年分別為 4,000 萬美元與 4,500 萬美元。配合該修訂,我們向 Perceptive 發行了 150,000 股普通股。
Turning to a review of our '25 guidance, which is also included in our fourth quarter 2024 financial results press release issued earlier today. For the 12 months ending December 31, 25, we expect total revenue in the range of $47.6 million to $49.0 million as compared to $48.1 million for the year ended December 31, '24.
接著回顧我們的 2025 年指引,該內容亦已納入我們今日稍早發布的 2024 年第四季財務結果新聞稿。在截至 2025 年 12 月 31 日的 12 個月期間,我們預期總營收介於 4,760 萬至 4,900 萬美元,相較於截至 2024 年 12 月 31 日止年度的 4,810 萬美元。
Our revenue guidance assumed advanced energy revenue in the range of $39.6 million to $41.0 million as compared to $38.6 million for the year ended December 31, '24, reflecting current trends.
我們的營收指引假設先進能量營收介於 3,960 萬至 4,100 萬美元,相較於截至 2024 年 12 月 31 日止年度的 3,860 萬美元,反映目前趨勢。
OEM revenue is expected to come in at approximately $8 million as compared to the $9.5 million for the year ended December 31, '24 as we return to more normalized customer ordering and order fulfilment. We anticipate gross margins of approximately 60% for the year and total operating expenses not to exceed $40 million. As a reminder, there's somewhat of a seasonality to the aesthetic space where quarterly revenue is normally the lowest in Q1 and Q3, and the highest in Q2 and Q4.
OEM 營收預期約為 800 萬美元,相較於截至 2024 年 12 月 31 日止年度的 950 萬美元,因我們將回到較為正常化的客戶下單與訂單履約節奏。我們預期全年毛利率約為 60%,且總營業費用不超過 4,000 萬美元。提醒各位,美學市場具有一定季節性,季度營收通常在第一季與第三季最低,在第二季與第四季最高。
We believe based on our projections, including the uptake of the AYON platform, working capital management, our strict cost controls, and the recent capital investment will yield cash into 2027.
我們相信,根據我們的預測(包括 AYON 平台的採用進展、營運資金管理、嚴格的成本控管,以及近期的資本投入),公司現金可支應至 2027 年。
This completes our prepared remarks. Charlie and I will now open the call for questions. Operator?
以上為我們準備好的發言內容。接下來 Charlie 和我將開放提問。接線員?
Operator
Operator
(Operator Instructions)
(接線員指示)
Matthew O'Brien, Piper Sandler.
Matthew O'Brien,Piper Sandler。
Matthew O'Brien - Analyst
Matthew O'Brien - Analyst
Morning, thanks for taking my questions. Matt, I just wanted to confirm you said 60% gross margin for '25 here?
早安,謝謝讓我提問。Matt,我只是想確認一下,你剛才說這裡對於 2025 年的毛利率是 60% 嗎?
Matthew Hill - Chief Financial Officer
Matthew Hill - Chief Financial Officer
Yeah, sorry -- yeah, great question. Yeah, we're looking at similar margins that we had for '24 into '25 at around 60%.
對,不好意思——對,問得很好。是的,我們預期 2025 年的毛利率會與 2024 年相近,大約在 60% 左右。
Matthew O'Brien - Analyst
Matthew O'Brien - Analyst
Okay, I'm just assuming there's probably some waiting from the, I don't know if it's the AYON launcher I'm just guessing we're just trying to figure out why that wouldn't recover just given the proportion of revenue coming from advanced energy versus OEM, especially, domestically.
好的,我只是猜想可能有一些因素在影響,例如,我不確定是不是 AYON 的上市推進之類的,我只是猜測;我們只是想了解,為什麼在先進能源(advanced energy)相較於 OEM(尤其是國內市場)占營收比重更高的情況下,毛利率不會回升。
Matthew Hill - Chief Financial Officer
Matthew Hill - Chief Financial Officer
So when you look at our gross margins, you're absolutely right there's a -- it depends on many things which include geographic mix, product mix, and then segment mix. And what we're looking at for '25 is that the current trends that we saw in '24 will continue into '25, which puts our estimated gross profit about at that around that 60% mark.
所以當你看我們的毛利率時,你說得完全正確——它取決於很多因素,包括地理區域組合、產品組合,以及事業部組合。而我們對 2025 年的看法是,2024 年看到的目前趨勢會延續到 2025 年,因此我們估計的毛利率大約會落在 60% 這個水準。
Matthew O'Brien - Analyst
Matthew O'Brien - Analyst
Got it. Okay, thanks for that. And then Charlie on AYON. Just the timing getting moved up here by 90 days. Congratulations on that. What are you assuming if anything in the guide for the back half for AYON? And then how should we think about your interest level or options in terms of accessing that product from a -- just outright capital purchase versus you know leasing kind of arrangement. How does -- how should we think about that?
了解。好的,謝謝你的說明。接著 Charlie,關於 AYON。時程提前了 90 天。恭喜。你們在下半年指引中,對 AYON 有沒有納入任何假設?另外,關於取得該產品的方式,你們的興趣或選項該怎麼看——例如直接資本購置,或是租賃之類的安排。也就是說——我們應該怎麼理解?
Charles Goodwin - President and Chief Executive Officer
Charles Goodwin - President and Chief Executive Officer
Yeah. So Matt, if you remember when we gave the guidance, we gave the guidance when we pre-announced in January to what it was going to be our -- and we had predicted that we wouldn't file AYON until the end of the first quarter. And so quite frankly we haven't updated anything in our guidance for that -- for the 90 days earlier and the reason for that is, look, we still predict that we will have approval in the first half of the year.
好的。Matt,如果你還記得我們給出指引時,是在 1 月預先公告時給的;當時我們預期 AYON 會在第一季末才送件申請。所以坦白說,我們並沒有因為提前 90 天而更新指引;原因是,你看,我們仍然預期會在上半年取得核准。
But obviously, we don't have approval as we sit here right now today and then when we do launch it in the back half of the year, we will have a soft launch like we always do with capital equipment to make sure that everything's working the way it's supposed to and all of that stuff and so the amount of revenue that is associated in our original budget for AYON is obviously not very big because of all of those factors.
但很明顯,截至今天此刻我們還沒有拿到核准;而且當我們在下半年推出時,會像我們一向對資本設備所做的那樣,先進行「軟性上市」,以確保一切如預期運作等等。因此,原始預算中與 AYON 相關的營收金額顯然不會很大,因為有上述所有因素。
So depending on when we get approval, depending on all of those things, we'll be able to update as the year goes on of what we think that AYON is going to do the revenue, okay? That's number one.
所以取決於我們何時取得核准、以及所有這些因素,我們會在年度進行過程中更新我們對 AYON 營收表現的看法,好嗎?這是第一點。
Number two for your second question is we actually believe that AYON will be something that all doctors -- are all surgeons are going to want to have in their operating room. Like we've said, we've taken every technology that is available today and we've upgraded that technology, we've made it state of the art, and then we've put everything together where the workflow and the efficiencies and everything else that go along with having a stand-alone system that is just for body contouring and all surgical procedures is something that exists everywhere else in surgery, but it doesn't exist in plastic surgery and so we think that this is going to have a great value proposition for the doctors as far as how they are going to be able to acquire it.
第二點,針對你的第二個問題,我們其實相信 AYON 會是所有醫師——所有外科醫師——都會想放在手術室裡的設備。如同我們所說,我們把目前可用的每一項技術都加以升級,做到最先進,並把所有東西整合在一起;其工作流程、效率,以及擁有一套專為體雕與所有外科手術打造的獨立系統所帶來的一切,在其他外科領域到處都有,但在整形外科並不存在。因此我們認為,這對醫師而言在取得方式上會有很強的價值主張。
There's a couple of things. Obviously, they'll be able to buy it outright. They'll be able to lease it. They'll do all of those things. What we will do is we've always try to take very good care of our existing customers first, so everybody today that has an Apyx One generator and has already upgraded and done all of those things will have the opportunity to get special pricing if they want to buy it for a limited time right away.
有幾件事。很明顯,他們可以直接買斷。也可以租賃。他們可以做所有這些安排。而我們會做的是:我們一向會先把既有客戶照顧好,所以目前所有擁有 Apyx One 產生器、且已經升級並完成相關事項的客戶,如果他們想在一段有限期間內立即購買,將有機會取得特別定價。
And then -- and we will then obviously take back competitive technologies and trade to make sure that we're getting AYON into every OR that is out there and so we've got a lot of programs that will be rolling out over time, a lot of things to show doctors that this is going to be a tremendous value for them to get involved with this technology and this system.
然後——我們也會回收競品技術並提供以舊換新,確保我們能把 AYON 帶進每一間手術室(OR)。因此我們有很多方案會隨時間推出,很多方式向醫師展示:參與這項技術與這套系統,將為他們帶來巨大的價值。
Matthew O'Brien - Analyst
Matthew O'Brien - Analyst
Got it. Thanks so much.
了解。非常感謝。
Charles Goodwin - President and Chief Executive Officer
Charles Goodwin - President and Chief Executive Officer
Yep.
好的。
Operator
Operator
Matt Hewitt, Craig-Hallum.
Matt Hewitt,Craig-Hallum。
Matt Hewitt - Analyst
Matt Hewitt - Analyst
Good morning. Thanks for taking the questions. Maybe the first one, you noted that the success that you had in the DTC campaign. I'm just curious, kind of what were the changes that were implemented and how do you see that playing out in '25?
早安。謝謝讓我提問。第一個問題,你提到你們在 DTC(直面消費者)活動上的成功。我想了解一下,具體做了哪些改變?以及你們認為這在 2025 年會如何發展?
Charles Goodwin - President and Chief Executive Officer
Charles Goodwin - President and Chief Executive Officer
So I think it's, you got to go back and remember that we didn't actually start doing our direct to consumer campaign until the middle of '23 and that's when we got the clearance for Renuvion used after liposuction in body contouring as a treatment for loose and lax skin, okay, so that's when it actually started.
我想你得回頭記得,我們其實直到 2023 年年中才真正開始做直面消費者的活動;那是在我們取得核准後,Renuvion 可用於抽脂後的體雕,作為治療皮膚鬆弛與鬆垮的療程,好嗎?所以那時才真正開始。
And quite frankly, our first foray into that, the first back half of '23, we actually didn't have the right partner and really didn't have the best message. In January of '24, we actually brought in a new PR partner that has been doing a tremendous job for us.
坦白說,我們第一次嘗試——也就是 2023 年下半年——其實沒有找對合作夥伴,也沒有最好的訊息傳達。在 2024 年 1 月,我們實際上引進了一家新的公關合作夥伴,為我們做得非常出色。
And we actually started rolling out the first programs of that in April of '24. So we actually, as we sit here today, actually haven't been doing this direct to consumer for almost even a year yet. And so the results that we have seen from the campaign, the results that we have seen that we are doing have just crushed every metric that we had before, and the fact of the matter is now is because of the adoption of GLP-1 drugs and because of the need of these patients that are losing 15% to 20% of their body weight, we are an incredible treatment for loose and lax skin.
而我們在 2024 年 4 月開始推出第一批相關方案。所以以今天此刻來看,我們做這個直面消費者的活動甚至還不到一年。因此,我們從活動中看到的成果、我們所做的結果,已經把我們之前的每一項指標都遠遠超越;而事實是,因為 GLP-1 藥物的採用,以及這些病患減重 15% 到 20% 體重的需求,我們對於皮膚鬆弛與鬆垮是一個非常出色的治療選項。
And we're the only FDA approved treatment for that, and the real answer is because of the amount of weight loss that they are going to have, that they are going -- most of those patients are going to benefit from a surgical intervention and we don't believe that many of the previous non-invasive therapies are going to be able to help with that much skin laxity, that the message is really resonating with consumers, influencers, doctors, everybody else is that this change has really been good for us from a direct to consumer point of view.
而且我們是唯一獲 FDA 核准用於此的治療方式;真正的答案是,由於他們將會有如此大幅度的減重,這些病患多數將受益於外科介入;我們不認為許多先前的非侵入式療法能夠處理這麼嚴重的皮膚鬆弛。因此,這個訊息確實在消費者、網紅、醫師以及其他所有人之間引起共鳴;從直面消費者的角度來看,這個變化對我們非常有利。
And so I think those are some of the main changes. Some of it was on us not having the right partner, and some of it is just what's going on in the marketplace.
所以我想這些就是一些主要改變。一部分是我們之前沒有找對合作夥伴,另一部分則是市場環境本身的變化。
Matt Hewitt - Analyst
Matt Hewitt - Analyst
That's great. And then I guess shifting gears a little bit, obviously, there remains -- it remains a challenging market, but it seems like you are doing better domestically than you are internationally. Is there anything that you can learn or that you can take from some of the improvements that you're implementing in the US to the external markets and what could that mean for an upside perspective for '25? Thank you.
很棒。接著我想稍微換個方向,顯然市場仍然——仍是個具挑戰性的市場,但看起來你們在國內市場的表現優於國際市場。你們是否能把在美國所推動的一些改善措施,學到的東西帶到海外市場?這對 2025 年的上行空間可能意味著什麼?謝謝。
Charles Goodwin - President and Chief Executive Officer
Charles Goodwin - President and Chief Executive Officer
Yeah. So If you look at why we think the US is doing better relative to the outside the United States, it has to do with the early adoption of GLP-1 drugs, quite frankly. And those drugs will be adopted everywhere in the world.
是的。所以,如果你看我們為什麼認為美國相較於美國以外表現更好,坦白說,這與GLP-1藥物的早期採用有關。而這些藥物將會在全球各地被採用。
The United States isn't the only nation that likes its food and consumes too much alcohol and all of that good stuff, so those drugs will make it all over the place, and we expect similar type results, throughout the rest of the world because we believe that surgery is going to be the key to take care of the needs that this specific group of patients has.
美國並不是唯一一個喜歡美食、飲酒過量以及諸如此類的國家,所以這些藥物會普及到各地;我們也預期世界其他地區會出現類似的結果,因為我們相信手術將是滿足這一特定患者族群需求的關鍵。
There was always a group of patients that needed surgery and benefited from surgery, but now that group because of the laxity in the skin is just continuing to grow, and it will for however long these drugs stay in vogue, if you will, and quite frankly, there's a lot of people that think that these drugs will be part of people's daily routines for sometimes the rest of their lives.
一直都有一群患者需要手術並且能從手術中受益,但現在由於皮膚鬆弛,這個族群只會持續擴大;只要這些藥物仍然流行,就會如此。坦白說,很多人認為這些藥物可能會成為人們日常作息的一部分,有時甚至是終其一生。
So we don't see that changing and quite frankly, we've always believed that surgery is really the thing that provides durable and transformational results in the aesthetic space. And our focus has always been on that. We think that we can become the most dominant company in surgical aesthetics, and our partnership with aesthetic surgeons is something that we look forward to for many years.
所以我們不認為這會改變;坦白說,我們一直相信,在醫美領域,手術才是真正能帶來持久且具變革性成果的方式。而我們的重點一直放在這上面。我們認為我們可以成為外科醫美領域最具主導地位的公司,而我們與醫美外科醫師的合作關係,是我們期待能維持很多年的。
Not only do we have a clinical team, not only are we marketing directly to consumers, but we've got a huge vested interest because of our consumable and disposable business to have them help grow their surgical practices.
我們不僅有臨床團隊,也不僅直接面向消費者行銷;同時,由於我們的耗材與一次性產品業務,我們也有非常重大的利害關係,去協助他們擴大其外科手術業務。
If they're doing better, we're doing better and so we're aligned perfectly from that scenario, and we think that disruption in the marketplace, to your point, it is a tough market, it's been being caused by the GLP-1 drugs and we think because of that major disruption that there are going to be companies that have the right technologies and products to treat those patients, and there's going to be other companies that don't have the right technologies to be able to treat those patients, and we think that we're at the forefront of that.
他們做得越好,我們就做得越好,因此在這個情境下我們的利益完全一致。我們也認為你提到的市場顛覆——這確實是一個艱難的市場——一直是由GLP-1藥物所造成;而正因為這種重大顛覆,市場上會有一些公司擁有正確的技術與產品來治療這些患者,也會有其他公司沒有合適的技術來治療這些患者;我們認為我們正站在最前沿。
Matt Hewitt - Analyst
Matt Hewitt - Analyst
That's great. Thank you.
太好了。謝謝。
Operator
Operator
Sam Eiber, BTIG.
Sam Eiber,BTIG。
Sam Eiber - Analyst
Sam Eiber - Analyst
Hi, good morning. Charlie, Matt, I appreciate you taking the questions this morning. Maybe I could just follow up on that last point you were making and maybe get your thoughts on what you're hearing. Or what you're seeing from accounts that maybe have started to adopt GLP-1s versus those who haven't and if you're getting that pull through on the utilization for Renuvion at this point.
嗨,早安。Charlie、Matt,感謝你們今天早上回答問題。也許我可以就你剛才提到的最後一點追問一下,想聽聽你們對於你們所聽到的情況的看法,或者你們從那些可能已開始採用GLP-1的客戶與尚未採用的客戶那裡看到什麼差異,以及目前你們是否已看到Renuvion使用量的帶動效應。
Charles Goodwin - President and Chief Executive Officer
Charles Goodwin - President and Chief Executive Officer
Yeah. Look, I think that, one of the things that we saw in the fourth quarter in particular was hand piece growth again in the United States, and I think that we had said that it would grow low double digits for the year and in fact it did and it was actually a little bit higher in the fourth quarter than that.
是的。我認為,特別是在第四季,我們看到美國的手柄(hand piece)再次成長;而且我想我們曾說過全年會有低雙位數成長,事實上確實如此,且第四季的成長甚至略高於那個水準。
So we are seeing that from our usage data and quite honestly, to have our consumables in the United States grow low double digits in an incredibly different, difficult aesthetic environment, I think speaks volumes to just that without me saying that it's being backed up in the numbers and that now is over 60% of our total advanced energy revenue.
所以從我們的使用數據來看確實如此;坦白說,在一個極其不同且艱難的醫美環境中,我們在美國的耗材仍能達到低雙位數成長,我認為這已充分說明一切——不需要我多說,數字已經證明——而且目前這部分已占我們先進能量(advanced energy)總營收的60%以上。
And so that focus and that drive and those patients coming in to have their loose and lax skin treatment is something that our doctors are seeing. Their surgical practices are good. They're solid. They're busy, and a lot of the disruption that happened in '24 from a revenue perspective for the offices was because of the non-invasive procedures were down almost a third.
因此,這樣的聚焦與推動,以及這些患者前來治療鬆弛皮膚的需求,是我們的醫師客戶正在看到的。他們的外科手術業務表現良好。很穩健。也很忙碌;而2024年診所端在營收面所發生的許多擾動,是因為非侵入式療程下滑了將近三分之一。
So we think that surgery is going to remain strong and we think that the doctors that are talking to these patients, focused on these patients and bringing these patients in their practices have never done better. '24 was the best year that they ever had, and we think more and more doctors obviously are moving to how they're going to deal with these patients and the offerings that they're going to have for these patients.
所以我們認為手術將會維持強勁;我們也認為,那些與這些患者溝通、專注於這些患者並把這些患者帶進診所的醫師,從未表現得更好。2024年是他們有史以來最好的一年;而我們認為越來越多醫師顯然正在轉向思考要如何應對這些患者,以及要為這些患者提供哪些服務。
And they're having to treat these patients differently because of the amount of laxity that is out there. So they're using combination procedures. They're doing all different kinds of things, and we're seeing this change happen within the aesthetic space. And that's why this aesthetic space has been disrupted the way that it has is because everything is having to evolve and to morph to be able to address this huge patient population that is out there.
而且他們必須以不同方式治療這些患者,因為皮膚鬆弛的程度更大。所以他們會使用組合式療程。他們會做各式各樣不同的處置;我們正在看到醫美領域內部發生這樣的變化。這也是為什麼醫美市場會以目前這種方式被顛覆——因為一切都必須演進與調整,才能應對這個龐大的患者族群。
Sam Eiber - Analyst
Sam Eiber - Analyst
Yeah. It makes a lot of sense. And maybe just as my follow up here, where are we maybe in terms of the upgrades for the Apyx One Console just want to understand if the majority of customers are now in the new system or if there's still more customers left to be converted here.
是的。這很合理。那我再追問一下,關於Apyx One Console的升級,目前大概進行到哪個階段?我想了解多數客戶是否已經在使用新系統,或是仍有更多客戶尚待轉換。
Charles Goodwin - President and Chief Executive Officer
Charles Goodwin - President and Chief Executive Officer
Yeah. It's a good question. So we are previously before AYON, the only reason that you would potentially need to upgrade to the Apyx One generator is if you wanted to use the micro hand piece. And that was more important to doctors that were doing a lot of fine features, facial work, all of those types of things.
是的。這是個好問題。在AYON之前,唯一可能需要升級到Apyx One產生器(generator)的原因,是你想使用micro手柄。而這對於那些做很多精細部位、臉部療程等的醫師更重要。
The vast majority of our customers focus on the body and everything else, and so there wasn't a huge incentive for them to upgrade to the Apyx One. Now that AYON is here, now obviously the Apyx One generator is the brains of the AYON system.
我們絕大多數客戶的重點在身體部位以及其他項目,因此他們升級到Apyx One的誘因並不大。現在AYON來了,Apyx One產生器顯然就是AYON系統的「大腦」。
And as I mentioned earlier, one of the things that we have always tried to do is to make sure that we're taking care of the people who have been our best customers and so for the customers that have an Apyx One or that are going to upgrade to an Apyx One before the launch of AYON we will give them the best pricing to upgrade to AYON once it is available and so we have a long ways to go for people that would need to upgrade to the Apyx One.
如我先前提到的,我們一直努力確保照顧那些一直以來最好的客戶;因此,對於已擁有Apyx One、或在AYON上市前會升級到Apyx One的客戶,一旦AYON可供使用,我們會提供他們升級到AYON的最佳價格;所以在需要升級到Apyx One的人群方面,我們還有很長的路要走。
Sam Eiber - Analyst
Sam Eiber - Analyst
Very good. Thanks for taking the questions.
很好。謝謝回答問題。
Charles Goodwin - President and Chief Executive Officer
Charles Goodwin - President and Chief Executive Officer
Yeah, thank you.
是的,謝謝。
Operator
Operator
Thank you. At this time I'd like to turn the floor back to Charlie Goodwin for closing remarks.
謝謝。此時我想把時間交回給Charlie Goodwin做結語。
Charles Goodwin - President and Chief Executive Officer
Charles Goodwin - President and Chief Executive Officer
Thank you. Thank you everyone for attending the call. We appreciate your support and we look forward to keeping you updated on our progress as we progress throughout the year. Thanks a lot.
謝謝。感謝各位參加本次電話會議。我們感謝各位的支持,也期待在今年接下來的進展中,持續向各位更新我們的進度。非常感謝。
Operator
Operator
Thank you. This does conclude today's teleconference. We thank you for your participation. You may not disconnect your lines at this time.
謝謝。今天的電話會議到此結束。感謝各位的參與。此時請先不要掛斷電話線。